They found that ALT-801 was able to mediate the specific killing of tumor cells in p53+/HLA-A2+ human melanoma (A375), breast cancer (MDA-MB231), and pancreatic carcinoma (PANC-1) xenograft models, in addition to having a fivefold longer terminal half-life than recombinant human IL-2 [127–129]. The gene discussed is TP53; the disease is neoplasm.